Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Cash from Financing Activities (2021 - 2025)

Prime Medicine (PRME) has disclosed Cash from Financing Activities for 5 consecutive years, with $562000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities rose 56100.0% year-over-year to $562000.0, compared with a TTM value of $151.5 million through Dec 2025, down 22.65%, and an annual FY2025 reading of $151.5 million, down 22.65% over the prior year.
  • Cash from Financing Activities was $562000.0 for Q4 2025 at Prime Medicine, down from $144.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $184.1 million in Q4 2022 and bottomed at -$1.3 million in Q1 2022.
  • Average Cash from Financing Activities over 5 years is $31.1 million, with a median of $194000.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities crashed 99.89% in 2023, then skyrocketed 231263.24% in 2024.
  • Year by year, Cash from Financing Activities stood at -$1.1 million in 2021, then surged by 17049.63% to $184.1 million in 2022, then plummeted by 99.89% to $194000.0 in 2023, then crashed by 99.48% to $1000.0 in 2024, then surged by 56100.0% to $562000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for PRME at $562000.0 in Q4 2025, $144.8 million in Q3 2025, and $197000.0 in Q2 2025.